EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
NCT03612739
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Sponsor decision
Conditions
AML, Adult
Myelodysplastic Syndromes
Interventions
BIOLOGICAL:
NKR-2 CAR-T Cells
Sponsor
Celyad Oncology SA